Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest NeuroPhage Pharmaceuticals Inc. Stories

2014-03-25 08:31:05

--Funds Will Advance Novel Approach for Treatment of Alzheimer's Disease and Other Diseases of Protein Aggregation-- CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced the completion of a $17 million Series D financing from existing and new investors to advance the Company's lead candidate, NPT088, and potential next-generation compounds toward clinical trials. NPT088 has the potential to treat a wide range of neurodegenerative diseases,...

2013-12-19 08:28:23

- Novel Approach to Target Disease-driving Misfolded Proteins - CAMBRIDGE, Mass., Dec. 19, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been awarded an $822,000 grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) for its second-generation drug candidate, NPT088, based on NeuroPhage's GAIM (general amyloid interaction motif) platform, which simultaneously targets multiple misfolded proteins central to many neurodegenerative...

2013-12-03 08:34:23

--Inaugural Effort to Unite World Dignitaries, Scientific Leaders and Finance Executives in Fight Against Dementia-- CAMBRIDGE, Mass., Dec. 3, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been invited to participate in the world's first G8 Dementia Summit. The G8 Summit is hosted by the British Prime Minister, David Cameron, and Health Secretary, Jeremy Hunt, and will be attended by G8 Health Ministers, pharmaceutical company leaders,...

2013-05-06 08:30:03

--After Successful Pre-IND Meeting, Company On Track to Advance Lead Compound NPT002 into Clinical Trials for Alzheimer's Disease in 2014-- CAMBRIDGE, Mass., May 6, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round. Merieux Developpement led the financing with participation from all current Neurophage investors, including...

2012-10-17 15:23:53

CAMBRIDGE, Mass., Oct. 17, 2012 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. announced today positive data with NPT001 in an alpha-synuclein pre-clinical model for Parkinson's disease (PD). The study was funded by The Michael J. Fox Foundation (MJFF). NPT001 is a first-in-class drug candidate with potential disease-modifying activity that disrupts and clears a variety of amyloid aggregates in the brain. In addition to reducing beta amyloid and tau aggregates in Alzheimer's...

2012-03-08 06:12:00

CAMBRIDGE, Mass., March 8, 2012 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a privately held biotechnology company focused on a novel approach for disaggregating misfolded proteins for the treatment and prevention of neurodegenerative diseases, announced today that it has secured $9.0 million in Series B-1. Dr. Michael Grundman, an Alzheimer's disease clinical expert, President and CEO of the consulting firm Global R& D Partners, LLC, has joined the NeuroPhage team to...

2012-02-16 09:12:00

CAMBRIDGE, Mass., Feb. 16, 2012 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. announced today that it has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct pre-clinical research targeting alpha-synuclein, a protein whose clumping is the pathological hallmark of Parkinson's disease (PD). This is NeuroPhage's first grant from MJFF. "It is a privilege to collaborate with MJFF toward the development of our novel therapeutic approach. This grant will provide...

2011-03-01 07:00:00

CAMBRIDGE, Mass., March 1, 2011 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a privately held biotechnology company developing a protein disaggregation platform for treatment of neurodegenerative diseases, announced today that it has secured $12.4 million in Series B financing, which will be mostly directed to the IND-enabling activities in preparation of a Phase 1 clinical trial for NPT001, NeuroPhage's lead product candidate for the treatment of Alzheimer's disease, and...